Nitrendipine: Indication, Dosage, Side Effect, Precaution

Generic Medicine Info Patient Medicine Information

This information is not country-specific. Please refer to the Thailand prescribing information.

Generic Medicine Info

Indications and Dosage

Oral
Hypertension

Adult: 20 mg daily as a single dose or in 2 divided doses; may be increased to 20 mg bid as necessary.
Elderly: Initially, 10 mg daily.

Hepatic Impairment

Initially, 10 mg daily.

Administration

Should be taken with food.

Contraindications

Pregnancy and lactation.

Special Precautions

Patient with cardiogenic shock or severe aortic stenosis. Hepatic impairment. Elderly.

Adverse Reactions

Eye disorders: Eye pain.
Gastrointestinal disorders: Nausea, gingival hyperplasia, gastrointestinal disturbance.
General disorders and administration site conditions: Lethargy, peripheral oedema.
Nervous system disorders: Dizziness, headache.
Psychiatric disorders: Depression.
Renal and urinary disorders: Increased micturition frequency.
Vascular disorders: Hypotension, flushing.

Drug Interactions

Increased plasma concentration with cimetidine and ranitidine. Decreased plasma concentration and exposure with bile acids (e.g. ursodeoxycholic acid, chenodeoxycholic acid).

Food Interaction

Grapefruit juice may increase the bioavailability of nitrendipine.

Action

Description: Nitrendipine is a dihydropyridine Ca channel blocker. It inhibits the influx of Ca ions through a voltage-dependent Ca channel in vascular smooth muscle cells.
Pharmacokinetics:
Absorption: Well absorbed from the gastrointestinal tract. Absolute bioavailability: Approx 10-30%. Time to peak plasma concentration: Within 1-3 hours.
Distribution: Plasma protein binding: Approx 98%.
Metabolism: Extensively metabolised in the liver. Undergoes extensive first-pass metabolism.
Excretion: Via urine and faeces (as inactive metabolites, <0.1% as unchanged drug). Terminal elimination half-life: Approx 10-22 hours.

Chemical Structure

Storage

Store below 25°C.

MIMS Class

Calcium Antagonists

ATC Classification

C08CA08 - nitrendipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.

References

Triggle DJ. Antihypertensive Mechanism of Action and Binding Sites of Nitrendipine. The American Journal of Cardiology. 1986 Sep;58(8):D35-D38. https://doi.org/10.1016/0002-9149(86)90423-6. Accessed 20/02/2023

Anon. Nitrendipine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 15/11/2022.

Buckingham R (ed). Nitrendipine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/11/2022.

Ditrenil (Siam Bheasach). MIMS Thailand. http://www.mims.com/thailand. Accessed 15/11/2022.

Preston CL (ed). Calcium-channel Blockers + Grapefruit Juice. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/11/2022.

Preston CL (ed). Calcium-channel Blockers + H2-receptor Antagonists. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 20/02/2023.

Preston CL (ed). Calcium-channel Blockers; Nitrendipine + Bile Acids. Stockley’s Drug Interactions [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 15/11/2022.

Disclaimer: This information is independently developed by MIMS based on Nitrendipine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by MIMS.com